Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.46 |
| ▸ | OGA | O60502 | 3/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710264 | 0.89 | OGA (0.53) | HIF1AOGAUTS2R | |
| SCHEMBL4709090 | 0.89 | OGA (0.53) | HIF1AOGAUTS2R | |
| SCHEMBL4709091 | 0.89 | OGA (0.53) | HIF1AOGAUTS2R | |
| SCHEMBL4709593 | 0.87 | HIF1A (0.46) | HIF1AOGAUTS2R | |
| SCHEMBL4709503 | 0.87 | HIF1A (0.49) | HIF1AOGAUTS2RMAPTSMN1; SMN2 | |
| SCHEMBL4712906 | 0.87 | HIF1A (0.49) | HIF1AOGAUTS2RMAPTSMN1; SMN2 | |
| SCHEMBL4710249 | 0.86 | OGA (0.50) | HIF1AOGAMAPT | |
| SCHEMBL4708805 | 0.86 | OGA (0.48) | HIF1AOGAMAPT | |
| SCHEMBL14453013 | 0.85 | SMN1; SMN2 (0.46) | HIF1AOGAUTS2RMAPTSMN1; SMN2 | |
| SCHEMBL4708524 | 0.85 | SMN1; SMN2 (0.46) | HIF1AOGAUTS2RMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | claimed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | claimed |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN | 2006-10-12 | — | — | US | claimed |
| CN-1703401-A | Substituted 1-benzyl-4-arylpiperazine analogs as ligands for melanin concentrating hormone receptors | NEUROGEN CORP (US) | 2005-11-30 | — | — | CN | claimed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | claimed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080044353-A1 | Combination Therapy for Weight Management | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1729762-A4 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1729762-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| CN-1703401-A | Substituted 1-benzyl-4-arylpiperazine analogs as ligands for melanin concentrating hormone receptors | NEUROGEN CORP (US) | 2005-11-30 | — | — | CN | disclosed |
| WO-2005094305-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6953801-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION | 2005-03-24 | — | — | US | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044353-A1 | Combination Therapy for Weight Management | CNR1, CNR2, MCHR1 | HIF1A 1353/4885OGA 1626/4885UTS2R 265/4885 |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | HIF1A 1295/4885OGA 4162/4885UTS2R 383/4885 |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | MCHR1, MCHR2, MC1R | HIF1A 1295/4885OGA 4162/4885UTS2R 383/4885 |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | HIF1A 1295/4885OGA 4162/4885UTS2R 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.